-DOCSTART- -X- O
[ -X- _ O
Image -X- _ O
: -X- _ O
see -X- _ O
text -X- _ O
] -X- _ O
Severe -X- _ O
acute -X- _ O
respiratory -X- _ O
syndrome -X- _ O
( -X- _ O
SARS -X- _ O
) -X- _ O
is -X- _ O
caused -X- _ O
by -X- _ O
a -X- _ O
newly -X- _ O
emerged -X- _ O
coronavirus -X- _ O
that -X- _ O
infected -X- _ O
more -X- _ O
than -X- _ O
8000 -X- _ O
individuals -X- _ O
and -X- _ O
resulted -X- _ O
in -X- _ O
more -X- _ O
than -X- _ O
800 -X- _ O
( -X- _ O
10–15 -X- _ O
% -X- _ O
) -X- _ O
fatalities -X- _ O
in -X- _ O
2003. -X- _ O
The -X- _ O
causative -X- _ O
agent -X- _ O
of -X- _ O
SARS -X- _ O
has -X- _ O
been -X- _ O
identified -X- _ O
as -X- _ O
a -X- _ O
novel -X- _ O
human -X- _ O
coronavirus -X- _ O
( -X- _ O
SARS-CoV -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
its -X- _ O
viral -X- _ O
protease -X- _ O
, -X- _ O
SARS-CoV -X- _ O
3CL -X- _ O
( -X- _ O
pro -X- _ O
) -X- _ O
, -X- _ O
has -X- _ O
been -X- _ O
shown -X- _ O
to -X- _ O
be -X- _ O
essential -X- _ O
for -X- _ O
replication -X- _ O
and -X- _ O
has -X- _ O
hence -X- _ O
been -X- _ O
recognized -X- _ O
as -X- _ O
a -X- _ O
potent -X- _ O
drug -X- _ O
target -X- _ O
for -X- _ O
SARS -X- _ O
infection. -X- _ O
Currently -X- _ O
, -X- _ O
there -X- _ O
is -X- _ O
no -X- _ O
effective -X- _ O
treatment -X- _ O
for -X- _ O
this -X- _ O
epidemic -X- _ O
despite -X- _ O
the -X- _ O
intensive -X- _ O
research -X- _ O
that -X- _ O
has -X- _ O
been -X- _ O
undertaken -X- _ O
since -X- _ O
2003 -X- _ O
( -X- _ O
over -X- _ O
3500 -X- _ O
publications -X- _ O
) -X- _ O
. -X- _ O
This -X- _ O
perspective -X- _ O
focuses -X- _ O
on -X- _ O
the -X- _ O
status -X- _ O
of -X- _ O
various -X- _ O
efficacious -X- _ O
anti-SARS-CoV -X- _ B-Intervention
3CL -X- _ I-Intervention
( -X- _ I-Intervention
pro -X- _ I-Intervention
) -X- _ I-Intervention
chemotherapies -X- _ I-Intervention
discovered -X- _ O
during -X- _ O
the -X- _ O
last -X- _ O
12 -X- _ O
years -X- _ O
( -X- _ O
2003– -X- _ O
2015 -X- _ O
) -X- _ O
from -X- _ O
all -X- _ O
sources -X- _ O
, -X- _ O
including -X- _ O
laboratory -X- _ B-Intervention
synthetic -X- _ I-Intervention
methods -X- _ I-Intervention
, -X- _ I-Intervention
natural -X- _ I-Intervention
products -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
virtual -X- _ I-Intervention
screening. -X- _ I-Intervention
We -X- _ O
describe -X- _ O
here -X- _ O
mainly -X- _ O
peptidomimetic -X- _ B-Intervention
and -X- _ I-Intervention
small -X- _ I-Intervention
molecule -X- _ I-Intervention
inhibitors -X- _ I-Intervention
of -X- _ I-Intervention
SARS-CoV -X- _ I-Intervention
3CL -X- _ I-Intervention
( -X- _ I-Intervention
pro -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
Attempts -X- _ O
have -X- _ O
been -X- _ O
made -X- _ O
to -X- _ O
provide -X- _ O
a -X- _ O
complete -X- _ O
description -X- _ O
of -X- _ O
the -X- _ O
structural -X- _ O
features -X- _ O
and -X- _ O
binding -X- _ O
modes -X- _ O
of -X- _ O
these -X- _ O
inhibitors -X- _ O
under -X- _ O
many -X- _ O
conditions -X- _ O
. -X- _ O

